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many diseases such as cancer and Alzheimer’s and has an impact on the body’s aging process.
External factors such as pollution, sunlight and smoking also trigger the production of free rad-
icals and the process of programmed cell death (PCD) that may occur in multicellular organ-
isms. Biochemical events lead to characteristic cell changes (morphology) and death. The
study was conducted to 42 male Orycytolagus Cuniculus rabbits. These animals were subdivided
into seven groups approaching the comparison between treatment with vitamin C and Di-Mer-
capto Succinic Acid (DMSA) including positive and negative control groups. Lead ions concen-
tration in blood, liver, kidney and brain were measured before and after treatments application.
Apoptotic related proteins P53 and Bcl2 were estimated beside histological studies of tissues.
Results revealed that it is more saving to use vitamin C as a lead chelator than DMSA. It is
also can be stated that severe lead toxicity can be carcinogenic by increasing the oxidative stressaddress: Biophysics Group,
gineering and Biotechnology
address: Faculty of Applied
i Arabia.
com (B.M. Raafat).
iﬁc Research & Technology.
. All rights reserved.
enter, Egypt.
lsevier
122 B.M. Raafat et al.in the biological systems as well as altering the balanced concentration of the apoptotic
proteins.
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Heavy metals such as lead, mercury, cadmium, and arsenic
contribute signiﬁcant potential threats to human health in
both occupational and environmental settings [23]. Lead is
the commonest of the heavy metals [22]. Lead is shown to have
very dangerous hazards on human health in all human life
stages, at ﬁrst, the fetal period, lead exposure has an adverse
effect on neurodevelopment [21]. Then at childhood, lead poi-
soning remains a critical environmental health concern. Low-
level lead exposure has been linked to decrease performance
on standardized IQ tests for school aged children [32].
In recent studies, lead has been shown to inhibit the activ-
ities of antioxidant enzymes, including glutathione peroxidase,
catalase and superoxide dismutase [6,12]. Furthermore, gener-
ation of reactive oxygen species (ROS), stimulation of lipid
peroxidation and depletion of antioxidant reserves have been
postulated to be major contributor to lead – exposure related
diseases [33,38]). ROS has a dual role [beneﬁcial and harmful]
in the biological systems [44]. Beneﬁcial roles involve the de-
fense against infectious agents; also at low concentration is
the induction of a mitogenic response. The harmful role is at
high concentration ROS is an important mediators of damage
to cell structures. It has been estimated that one human cell is
exposed to approximately 1.5 · 105 oxidative hits a day from
hydroxyl radicals and other such reactive species [3]. The hy-
droxyl radical is known to react with all components of the
DNA molecule: damaging, both the purine and pyrimidine
bases also deoxyribose backbone [11]. Permanent modiﬁcation
of genetic material resulting from these ‘‘oxidative damage’’
incidents represents the ﬁrst step involved in mutagenesis, car-
cinogenesis and aging. To date, more than 100 products have
been identiﬁed from the oxidation of DNA.
The nuclear factor, P53, plays a key role in protecting a cell
from tumourigenesis [19]. Due to its ability to halt the cell cycle
or initiate apoptosis if cell is damaged, it is often called a ‘‘tu-
mor suppressor’’. It is a transcriptional factor encoded by
TP53 gene [42]. The name of P53 refers to its apparent molec-
ular mass: it runs as a 53 kDa protein on SDS–page but based
on calculation from its amino acids residues, P53’s mass is
actually 43.7 kDa. This difference is due to its high number
of proline residues on the protein which slows the migration
on SDS–page. In humans, P53 is encoded by the TP53 gene lo-
cated on the short arm of chromosome 17.
Mutations that deactivate P53 in cancer usually occur in the
DNA binding core domain (DBD). Most of these mutations
destroy the ability of the protein to bind to its target DNA se-
quences, and thus prevents transcriptional activation of these
genes. As such, mutations in the DBD are recessive loss-of-
function mutations. Molecules of P53 with mutations in the
oligomerisation domain (OD) dimerise with wild-type P53,
and prevent them from activating transcription. Therefore,
OD mutations have a dominant negative effect on the function
of P53.The P53 protein is estimated to have several hundred trans-
regulation target genes that affect pathways including apopto-
sis, DNA damage repair, and cell-growth arrest [48].
Other family of genes is Bcl2, Bcl2 is the prototype for a
family of mammalian genes and the proteins they produce.
They govern mitochondrial outer membrane permeabilization
(MOMP) and can be either pro-apoptotic (Bax, BAD, Bak and
Bok among others) or anti-apoptotic (including Bcl2 proper,
Bcl-xL and Bcl-w, among an assortment of others). There
are a total of 25 genes in the Bcl2 family known to date.
Bcl2 derives its name from B-cell lymphoma 2, as it is the sec-
ond member of a range of proteins initially described as a re-
ciprocal gene translocation in chromosomes 14 and 18 in
follicular lymphomas.
There are a number of theories concerning how the Bcl2
gene family exerts their pro- or anti-apoptotic effect. An
important one states that this is achieved by activation or inac-
tivation of an inner mitochondrial permeability transition
pore, which is involved in the regulation of matrix Ca2+, pH
and voltage. It is also thought that some Bcl2 family proteins
can induce (pro-apoptotic members) or inhibit (anti-apoptotic
members) the release of cytochrome c into the cytosol which,
once there, activates caspase-9 and caspase-3, leading to apop-
tosis. Although Zamzami et al. [53] suggest that the release of
cytochrome c is indirectly mediated by the PT pore on the inner
mitochondrial membrane, strong evidences suggest an earlier
implication of the MAC pore on the outer membrane [25,28].
Many of the genes that control apoptosis during tumor
development can also inﬂuence treatment sensitivity, for exam-
ple, the P53 tumor suppressor promotes apoptosis in response
to stress-inducing stimuli, and, in turn, P53 inactivation facil-
itates tumor development [45]. Anticancer agents also activate
P53 to promote apoptosis, and loss of P53 function can pro-
mote drug resistance in cultured cells and animal models
[27,36]. Hence, P53 mutations can simultaneously account
for a survival advantage during tumor development and inher-
ent resistance to chemotherapeutic drugs. Of note P53 can also
engage several cell-cycle check points and trigger cellular
senescence [24,46,8,10,43], although the extent to which these
processes contribute to drug action in vivo is not known.
So, the aim of this work was to investigate the efﬁciency of
the oxidative stress resulted from lead poisoning as a known
toxic agent on the apoptosis related proteins as well as test
to what extend heavy metals chelators can reverse the poison-
ing hazards.2. Materials and methods
The study was conducted to 42 male Orycytolagus Cuniculus
rabbits. They were individually housed in stainless steel cages
in an air conditioned room with temperature maintained at
25 ± 2 C under a 12 h light/dark cycle from 6 am to 6 pm
and free access to foods was allowed. The food is checked
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result in results interference. The approximate animal weight
was 1.25 kg (±0.1 kg). Animal design was approved by the Eth-
ical Committee of the National Research Center (NRC). Before
dosing of rabbits they were acclimatized for 7 days then ran-
domly subdivided into six groups (7 animals each) as follow:
Group I: Negative control group. This group includes ani-
mals never received any treatment.
Group II: Positive control group. This group includes ani-
mals received lead (as lead acetate) in water for 21 days
with no treatment application.
Group III: This group includes animals received lead ace-
tate in drinking water for 21 days and then treated with
50 mg/kg DMSA (meso 2,3 dimercaptosuccinic acid) three
times per week for another 21 days after cessation of lead
exposure.
Group IV: This group includes animals received lead ace-
tate in drinking water for 21 days and then treated with
50 mg/kg DMSA three times per week for another 21 days
with continuous exposure to lead.
Group V: This group includes animals received lead acetate
in drinking water for 21 days and then treated with 420 mg/
kg ascorbic acid three times per week for another 21 days
after cessation of lead exposure.
Group VI: This group includes animals received lead ace-
tate in drinking water for 21 days and then treated with
420 mg/kg ascorbic acid three times per week for another
21 days with continuous exposure to lead.
Lead acetate was given to animals in drinking water with
concentration 1000 ppm. Acidiﬁcation of water is essential
for dissolving lead acetate so 1 ml of conc. hydrochloric acid
was added per liter of deionized water. This concentration
(1000 ppm lead acetate) is known to induce the desired level
of toxicity in blood and other soft tissues. DMSA (50 mg/kg
body weight) was orally administrated to rabbits three times
per week. Ascorbic acid (420 mg/kg body weight) was orally
administrated to rabbits three times per week.
Sample preparation attention was paid to avoid contamina-
tion, therefore every item from the moment of sampling until
analysis was regarded as potential source of contamination
and was checked not to contain or leach detectable amount
of any contaminant. Sample collection was performed after
ﬁnishing the 21 days for the ﬁrst group and 42 days for the
rest.Table 1 Blood, brain, bone and liver lead concentration in anima
(mean ± SD).
Group Blood lead Conc.
(lg/dl)
Brain lead Conc.
(lg/100 g dry wt.)
GI 0.00 0.00
GII 87.16 ± 5.7 27.69 ± 2.06
GIII 37.56 ± 5.5
** 23.67 ± 2.35**
GIV 45.35 ± 4.7
** 23.82 ± 2.18**
GV 27.67 ± 3.6
** 13.18 ± 2.17**
GVI 36.85 ± 2.9
** 17.50 ± 2.75**
* P< 0.01, compare between each group and control.
** P< 0.5 compare between each group and control.
*** P< 0.001 compare between each group and control.Blood samples were collected for the biochemical investiga-
tions from left ear vein of the rabbit by a suitable syringe for
this purpose and stored in tubes containing heparin at
70 C till the time of analysis. Tissue specimens (liver, brain,
kidney, left femur) were collected.
Determination of apoptosis related proteins P53 and Bcl2
was performed by using ELISA technique. P53 is determined
by Assay designs kit package catalog No. 900-117. Bcl2 is
determined by Assay designs kit package catalog No. 900-
133.
Determination of blood lead level was carried out accord-
ing to the method described in the Pye-unicum instruction
manual (1980) using a Pye-unicum SP 90 series Atomic
absorption spectrophotometer. Ashing technique was done
by taking 2 ml blood added to 2 ml of HNO3 of speciﬁc gravity
1.3 plus one milliliter of HCl in a 100 ml beaker to be placed on
hot plate till dryness. When the contents become almost dry,
the side of the beaker was ﬂushed with few drops of water,
then 3 ml of HNO3, was added and the contents will be di-
gested again to dryness. The deproteinized blood was dis-
solved, centrifuged and transferred quantitatively to the
original volume of the sample is 2 ml. Then the sample was
introduced into the apparatus for reading, the point of inter-
section between the sample reading and the standard curve
indicates the contents of lead in the blood sample expressed
in mg/dl.
Lead content in tissues was investigated, where dried bone
was crushed with acid wash glass/glass motor and pestle. The
lead concentration of the various tissues was determined by
atomic absorption with a graphite furnace utilizing modiﬁed
methods of Yeager et al. [52]. The method involved a chelation
and extraction technique in which lead was ﬁrst complexed
with fresh 2% APDC and then extracted into MIBK. The
MIBK layer was dried down and the sediment was digested/
reconstituted into conc. nitric acid and injected into the atomic
absorption spectrophotometer graphite furnace and will be
measured at 283 nm.
All soft tissue and bone lead concentrations was reported as
micrograms lead/100 g tissue. This allowed an approximate
comparison of the tissue lead concentration to the blood lead
concentration.
Measurement of auto-oxidation rate was carried out spec-
trophotometrically as described by Wallace et al. [47] and
Guillochon et al. [18] in air saturated 0.1 M phosphate buffer
of pH 7.05 with 2 mg/ml HbO2. The pH was checked before
and after each experiment and spectra of hemoglobin werels treated with vitamin C and DMSA as compared to control
Bone lead Conc.
(lg/100 g dry wt.)
Liver lead Conc.
(lg/g wet wt.)
0.00 0.00
754.4 ± 29.62 134.85 ± 8.2
450.17 ± 57.78** 34.92 ± 4.94**
552.64 ± 27.83** 46.60 ± 4.49**
395.25 ± 28.93** 26.64 ± 4.04**
343.1 ± 19.16** 45.15 ± 5.01**
Table 2 Determination of P53 and Bcl2 in rabbits exposed to
lead poisoning as well as those treated with vitamin C and
DMSA as compared to control (mean ± SD).
Group P53 (pg/ml) Bcl2 (pg/ml)
GI 4.18 ± 0.058 3.461 ± 0.205
GII 4.27 ± 0.14 3.673 ± 0.09
GIII 7.28 ± 1.17
*** 4.221 ± 0.55**
GIV 4.71 ± 0.29
*** 3.881 ± 0.24**
GV 16.28 ± 1.61
** 3.107 ± 0.12**
GVI 5.15 ± 1.14
** 3.472 ± 0.11**
*P < 0.01 compare between each group and control.
** P< 0.5 compare between each group and control.
*** P < 0.001 compare between each group and control.
Table 3 Superoxide dismutase and glutathione peroxidase in
rabbits exposed to lead poisoning as well as those treated with
vitamin C and DMSA as compared to control (mean ± SD).
Group SOD (U/ml) GPx (U/ml)
GI 147.98 ± 1.28 5758.10 ± 58.25
GII 196.5 ± 9.48 8787.61 ± 864.41
GIII 76.75 ± 10.45
** 6218.33 ± 927.53**
GIV 98.0 ± 15.05
** 7193.92 ± 556.97**
GV 38.25 ± 7.66
** 3921.07 ± 590.90**
GVI 64.07 ± 5.27
** 5308.50 ± 538.54**
*P < 0.01, ***P < 0.001 compare between each group and control.
** P< 0.5 compare between each group and control.
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ing auto-oxidation rate measurements.
Determination of superoxide dismutase (SOD) activity was
carried out by a RANDOX kit package, catalog No. SD 125
[30].
Determination of glutathione peroxidase activity was car-
ried out by a RANDOX kit package, catalog No. RS 504
according to [49].
Ultrathin sections of the kidney, liver and brain tissues was
collected and then examined by electron microscope in the Na-
tionalCancer Institute using Jeol jem-100s Electronmicroscope.
3. Results
Data in Table 1 shows the lead ions concentration in animals
treated with both vitamin C and Di-Mercapto Succinic Acid
(DMSA). Animals treated with ascorbic acid recorded the low-
est blood lead values either with or without continuity of poi-
soning intoxication. Subgroup treated with ascorbic acid from
the beginning of the poisoning application revealed lower val-
ues of lead ions concentration in all body compartment as
compared to control. Attention should be drawn to the boneA
bsorbance 
at 630 nm
 
Figure 1 Auto-oxidation rate of animals hemoglobin after intoxicatio
DMSA with and without continuous exposure to lead.concentration in groups treated with both chelator as the dec-
rement ratio is lower than that calculated in other body
compartments.
Treatment of animals with ascorbic acid after cessation of
lead poisoning (GIII) led to a signiﬁcant decrease in Bcl2
(P< 0.05) compared to intoxicated animals (GII). Concomi-
tant administration of both lead acetate and ascorbic acid
(GVI) led to insigniﬁcant change in Bcl2 level (P> 0.05) com-
pared to intoxicated animals (GII). The overall picture depicts
that Bcl2 concentration was minimally affected compared to
the changes observed in P53 proteins. Ascorbic acid increased
the level of the antiapoptotic protein only after cessation of
lead acetate treatment (Table 2).
Data shown in Table 3 revealed the lower antioxidant activ-
ity in rabbits received ascorbic acid after the stoppage of the
poisoning process. Ascorbic acid groups either with or without
continuity of lead poisoning showed lower antioxidant activity
as compared to those obtained from the DMSA treated
animals.
It is obviously shown that the highest rate of hemoglobin
conversion was recorded in animals intoxicated with lead
and did not receive any type of treatment. The rate of auto-
oxidation in hemoglobin of animals treated with vitamin CGVI
GI
GIII
GIV
GV
GII
Time (hr) 
n with lead as compared to animals treated with ascorbic acid and
Figures 2–8 Light microscope examination of liver on treated animals as compared to normal controls. (2 and 3) show control liver. (4
and 5) show liver of animals received lead ions with no treatment. (6) shows liver of animals received lead intoxication followed by DMSA
treatment. (7 and 8) show liver of animals treated with ascorbic acid and DMSA, respectively.
Figures 9–12 (9 and 10) Highly degenerated mitochondria, degeneration of the nucleus in group I. (11 and 12) Apoptosis in group I
hepatocytes. (13 and 14) Apoptosis in group II hepatocytes. (15–17) Healthy hepatocytes in group III. (18) Healthy hepatocytes in group V.
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those treated with DMSA.
3.1. Histopathological study
3.1.1. Light microscopic examination of liver
Normal liver are shown in Figs. 2 and 3. Liver transverse sec-
tions of lead acetate administration for 21 days showing severe
hydropic and vascular degeneration were seen in the hepato-
cytes mainly periphery of the centrilobular zone (Fig. 4). In
these areas, hepatocytes were swollen, pyknoses, vascular
and picnotic. The central veins as well as portal veins engorged
with blood partially the central vein (Figs. 4 and 5). A clear
dilatation and congestion of the portal veins was noticed, in
addition periportal necrosis of the hepatocytes that surround
the portal areas, and the inﬂammatory inﬁltration was seen
(Fig. 5). Microscopic examination of rabbit liver in group 2
(21 days of exposure to lead in drinking water followed by an-
other 21 days of DMSA treatment) showed low level of pykno-
sis in the hepatocytes nuclei (Fig. 6). Moderate vacuolation in
the cytoplasm of hepatocytes could be counter. The portal area
apparently showed no changes (7 and 8) show nearly liver
examination of animals treated with ascorbic acid and DMSA,respectively. It was very noticeable that animals received
DMSA after stoppage of lead intoxication in water showed
lower effects as compared to those the poisoning process
continuing with the treatment application.
3.1.2. Electron microscopic examination of liver
It revealed the presence of some degenerated mitochondria in
the form of spots can be seen in liver tissues after lead acetate
administration for 21 days (GII) (Fig. 9). The cytoplasm of
hepatocytes is highly vacuolated distracted and showing no
characteristic signs of regular healthy cells (Fig. 10). In addi-
tion to very small or completely degenerated nucleus in hepa-
tocytes were seen with absence of most of the cell organelles
(Figs. 11 and 12). Figs. 13 and 14 shows binucleated hepato-
cytes in some liver rabbit exposure to lead in drinking water.
The signs of regeneration were less evident in both groups
III & V (Figs. 15–18).The hepatocytes appeared more or less
as normal liver in group V as shown in Fig. 18.
3.1.3. Light microscopic examination of kidney
Histopathological examination of kidney section of group II
showed inﬂammatory inﬁltration beside the congested renal
corpuscle, hemorrhagic areas in the interstitium (Figs. 19
Figures 19–24 (19–21) Highly degeneration of renal tubules, inﬂammatory inﬁltration in group II. (22) Highly degeneration of renal
tubules. (23 and 24) Normal structure of corpuscles renal and tubules in rabbit treated with ascorbic acid or DMSA.
Figures 13–18 (13 and 14) Apoptosis in group III hepatocytes. (15–17) Healthy hepatocytes in group III. (18) Healthy hepatocytes in
group V.
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Figures 25–28 (25 and 26) Bone of animals intoxicated with lead for 21 days. (27 and 28) Bone of animals treated with vitamin C for
another 21 days after stoppage of lead intoxication.
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some tubules show desquamation of its epithelial as in animals
suffered from lead poisoning (Figs. 21 and 22). However, a
normal structure of corpuscles renal and tubules were observed
when rabbit treated with ascorbic acid or DMSA (Figs. 23 and
24).
3.1.4. Light microscopic examination of bone marrow
A variety of histopathological lesions was observed in GII
on H&E-stained sections from bone marrow, lead has been
shown to produce deﬁnite morphological changes in the
bone marrow. Fig. 25 shows the activities of hematopoiesis
decrease strongly with numerous fat cells are present in
the bone marrow. In addition to shrinkages where seen in
some granules (Fig. 26). Marked variation in the tissue den-
sity between control (Figs. 27 and 28) and treated groups
was noticed. Treatment with ascorbic acid with no further
lead poisoning increased the activity of hematopoiesis and
decrement of the fat cells (Fig. 27c). While, many of fat cells
are still present in bone marrow after the treatment with
DMSA (Fig. 28).3.1.5. Electron microscopic examination of bone
It revealed the presence of depletion and lysis of granules in
hematopoietic cells in animals intoxicated with lead (Fig. 29).
Figs. 30 and 31 showed lysis in cell membrane and in some
granules in hematopoietic cells while complete loss of the nu-
cleus with most of cell organelles are seen in some bone mar-
row cell before treatment (Fig. 32). In addition, in some
TEM section shown hemorrhage in bone marrow where pres-
ent before treatment. Figs. 33 and 34 showed healing of some
cellular bone marrow in group III. Figs. 35 and 36 shows in-
creased granules in group V.
3.1.6. Histopathological ﬁndings in the brain
Microscopically, the brains of the lead exposed animals
showed diffuse vacuolar degeneration, damages nerve cells
and increased neovascularization of the cerebral white matter
(Fig. 38). A large number of degenerating (i.e., shrunken,
argyrophilic) neurons were observed in the hippocampus with
clear edema and apoptosis were more signiﬁcant and moderate
neuroﬁbrillary degeneration is quite illustrated (Figs. 37 and
39). In addition, neuronal degeneration and mild spongy
Figures 29–36 (29–32) Bone marrow of animals intoxicated with lead for 21 days (GII). (33–36) Bone marrow of animals treated with
vitamin C for another 21 days after stoppage of lead intoxication.
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facial nuclei were observed in group II animals. In the neural
cell bodies, Nissl bodies disappeared and tigrolysis was ob-
served. Neural cells looked globular and spindle shaped, and
a strong degenerative change was observed (Figs. 40 and 41).
The number of glial cells also increased remarkably in all of
the brain lesions that were examined (Fig. 43). In the brain cor-
tex, degeneration in some of the neuron cells, in the lumens of
the blood vessels, dilation, hemorrhagia and free ﬂoating
erythrocytes were observed (Fig. 42). It is very noticeable that
animals received ascorbic acid after stoppage of lead intoxica-
tion in water showed lower effects as compared to those ani-
mals the poisoning process continuing with the treatment
application. A moderate changes in the structure of rabbit
brain was observed after treatment with ascorbic acid. A mod-
erate number of degenerating neurons were observed in the
hippocampus with clear edema (Figs. 43 and 44). The number
of glial cells still increased remarkably in all of the brain lesions
especially in the brain cortex with marked hemorrhagia and
blood vessels dilation (Fig. 45).4. Discussion
Lead is one of the most pollutants that affect our life. In the
words of environmental health and environmental medicine,
lead exposure remains one of the most important problems
in terms of prevalence of exposure and public health impact.
Despite decades of intensive researches, lead toxicity remains
one of the most, if not the most, the studied subjects of all
within the ﬁeld of environmental health. It is a heavy metal
that can pollute air, water and food causing a numerous
changes in the human body that may be reversible or not
[20]. Lead toxicity may cause loss of vision by affecting eye ret-
ina [17]. It may cause circulatory problems, and it may cause
excretory problems by affecting the kidney [29]. Lead also
may cause acute brain herniation [4,5]. There is a great associ-
ation between hypertension and biological markers for leadexposure [26]. Our collective data assessments of lead concen-
tration in rabbit tissues gave evidence that vitamin C is a good
chelator of lead. Vitamin C revealed better results when com-
pared to those obtained by DMSA treatment protocol regard-
ing all body lead poles. A great attention should be derived to
lead concentrations in all sites of animals those received treat-
ment doses after removing the objects away from the pollution
source. That is way; treatment must be started from removing
the pollution sources or even moving the subjects away from
the polluted environment. Animals treated with ascorbic acid
after stoppage of lead acetate exposure showed the lowest lead
concentration in blood as compared with that treated with
ascorbic acid with continuous exposure of lead acetate, the fact
that vitamin C is water soluble vitamin offers us the opportu-
nity to use such high concentration of the vitamin since the ex-
cess of the vitamin will be excreted from the body. The current
recommended dietary allowance (RDA) of vitamin C is 75 mg
for woman and 90 mg for men and the lack of vitamin C will
manifest within weeks and may result in death in 5–6 months
[7].
From the blood plasma, the absorbed lead is distributed to
other organs. Among the soft tissues, the liver and the kidney
attain the highest concentrations [2,40,1]. In those organs, lead
occurs as intranuclear inclusion bodies [15]. Lead does, to
some extent, pass the blood–brain barrier [2,40]. A large pro-
portion of the absorbed lead is incorporated into the skeleton
[2,50,39,31]. The skeleton contains more than 90% of the body
burden of lead; in lead workers, that fraction may be even
higher [2]. The lead content in the skeleton is not a homoge-
nous pool. By analogy with calcium, there is probably a small,
but rapidly exchangeable, skeletal lead pool. In addition, there
are at least two other pools: one is contained in trabecular
bone [the spongy bone (e.g., invertebrae and in the heads of
the long bones)], [2,37]. In addition, there is a pool in cortical
bone (the compact bone, e.g., in the hollow cylinder in the long
bones; [34,40,41,16]. The skeleton contains approximately
20% trabecular and approximately 80% cortical bone, but
the surface areas of the two types of bones are similar. Thus,
Figures 37–45 (37–42) Degeneration and damages in the brain tissue in group II. (43–45) Degeneration and damages decrease in brain
tissue in group III.
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than that of the cortical one [37]. The turnover rate of lead
in the skeleton is higher in infants than in adults [9]. The lead
content in the skeleton in subjects without occupational expo-
sure varies in different areas of the world. It was very low,
probably only a few milligrams, in prehistoric subjects living
in a world without trafﬁc and industries [13], approximately
10 mg in contemporary Scandinavians [37,14], and approxi-
mately 100 mg in subjects in the United Kingdom [2] and the
United States [13], although the amounts have most probably
decreased lately. In Table 2 the results came also matched with
Table 1 in that ascorbic acid treated group after stoppage of
lead toxicity has the lowest lead concentration than the other
groups.
The P53 is one of the most important apoptosis proteins
present in the cell, and by knowing that the lead intoxication
raises the oxidative stress of the cell and the researchperformed by Xu et al. [51] that show that the P53 value
increases with increasing the lead acetate concentration value
till a certain value then a decrease in P53 concentration was
observed. The apoptosis is the other option that the P53 can
perform other than repairing the genetic code. P53 showed a
dramatic increase in the groups treated with ascorbic acid
and DMSA after lead intoxication process was stopped,
regarding both control group animals who receive lead poison-
ing with no treatment and animals of the last group, those
received ascorbic acid treatment in the same time with contin-
uous lead poisoning. Our results were in agreement with Xu
et al. [51] as P53 value raised with increasing the lead acetate
concentration then decreased again. It is suggested that one
of the carcinogenic mode of action of lead intoxication is that
it reduce the level of P53 concentration.
Bcl2 is one of the important proteins in the cell that has anti-
apoptotic effect and by investigating the Bcl2 concentration. It
130 B.M. Raafat et al.is noticeable that there are no signiﬁcant changes by using
either ascorbic acid or DMSA as a treatment with or without
continuous lead exposure. Of course increasing oxidative stress
caused by lead poisoning may be the reason of elevated P53
value, so by measuring SOD values in all groups as a marker
of oxidative stress. Here we found that the lowest level of
superoxide dismutase activity was recorded in the group of
animals received ascorbic acid treatment after lead poisoning
stoppage. Also these results matches the fact that vitamin C
is a naturally synthesized inside normal cells and lead poison-
ing causes alteration of vitamin C metabolism [35]. Table 3
illustrates glutathione peroxidase activity of all groups com-
pared to control. Highly signiﬁcant decrease was measured
in all groups after treatment with ascorbic acid. Glutathione
peroxidase activity showed similar results as SOD activity.
Both SOD and glutathione peroxidase act as antioxidant and
called the bodyguards.
The auto-oxidation rate as in Fig. 1 is one of the ways
that measures the capability of hemoglobin to carry oxygen,
so we investigate the auto-oxidation rate of animals hemo-
globin of all groups compared to normal control. It is obvi-
ously shown that the highest rate was recorded to the
control group. Hemoglobin auto-oxidation rate of animals
treated with ascorbic acid showed lower rates as compared
to control group. In vitamin C treatment application stop-
page of further exposure to lead poisoning reduce the rates
by which normal hemoglobin converted into non-functional
hemoglobin.
Histopathological results supported the biochemical and
molecular results. It was noticed that, the repairing mechanism
that took place in the liver and kidney after treatment was
combined with an increase of P53 concentration value with
no signiﬁcant change in Bcl2 specially, in case of treatment
with vitamin C.
In conclusion, it is very safe to state that vitamin C act as a
better lead chelator than DMSA and has the ability to control
the intoxication side effects. It is also can be stated that severe
lead toxicity can be carcinogenic by increasing the oxidative
stress in the biological systems as well as altering the balanced
concentration of the apoptotic proteins.References
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